Xeris Glucagon to be Branded “Gvoke”; Xeris Issues 5M Additional Shares
Xeris announced a proposed public offering of 5M additional shares; and, in the S-1 document, disclosed the commercial name of its stable glucagon as “Gvoke” believed to be pronounced (gee’-voke), which appears to be a play on the word “evoke.” Below, FENIX provides key highlights from the S-1 filing, thoughts on the impending Xeris glucagon launch in H2 ’19 (June 10, 2019 PDUFA date), and insight on potential read-through to Xeris from FDA’s upcoming decisions on Sanofi/Lexicon’s sotagliflozin in T1DM (March 22, 2019 PDUFA date) and Lilly’s nasal glucagon (PDUFA believed to be in April 2019).
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.